Uploaded April 2026 | Updated September 2026, 3 weeks ago
Mirxes in Singapore enhances cancer diagnostics with AI powered by Oracle Cloud Infrastructure and Oracle AI Database. Discover how intelligent platforms improve clinician efficiency and patient outcomes. Mirxes, a Singapore-based biotech company specializing in blood-based diagnostics for early cancer detection, is leveraging Oracle technology to scale innovation in healthcare. Ah Jung Jeon, Lead of AI Enablement and Bioinformatics at Mirxes, shares how the organization is developing advanced screening solutions for gastric, lung, and colorectal cancers while expanding toward multi-cancer detection.
As Mirxes grows across Southeast Asia and beyond, the company faced increasing operational challenges, including managing large volumes of clinician inquiries about diagnostic products. Manual processes created inefficiencies and delayed response times. In collaboration with Oracle AI Customer Excellence Center, Mirxes co-developed an intelligent clinician AI assistant using Oracle Cloud Infrastructure and Oracle AI Database to streamline communication and improve access to critical information.
This AI-driven solution is designed to support, not replace, medical professionals by reducing administrative burden and enabling faster access to accurate scientific insights. Built with strong safeguards, curated knowledge, and compliance considerations, the platform ensures trusted and responsible AI use in healthcare environments. Looking ahead, Mirxes plans to expand this capability into a broader data and AI platform that integrates clinical and genomic data, enabling more advanced diagnostics and improved patient care.
Follow us here:
LinkedIn: https://social.ora.cl/60035eXuF
X: https://social.ora.cl/6008abVgG
Instagram: https://social.ora.cl/60095eXDN
Facebook: https://social.ora.cl/60065enQp
Mirxes in Singapore enhances cancer diagnostics with AI powered by Oracle Cloud Infrastructure and Oracle AI Database. Discover how intelligent platforms improve clinician efficiency and patient outcomes. Mirxes, a Singapore-based biotech company specializing in blood-based diagnostics for early cancer detection, is leveraging Oracle technology to scale innovation in healthcare. Ah Jung Jeon, Lead of AI Enablement and Bioinformatics at Mirxes, shares how the organization is developing advanced screening solutions for gastric, lung, and colorectal cancers while expanding toward multi-cancer detection.
As Mirxes grows across Southeast Asia and beyond, the company faced increasing operational challenges, including managing large volumes of clinician inquiries about diagnostic products. Manual processes created inefficiencies and delayed response times. In collaboration with Oracle AI Customer Excellence Center, Mirxes co-developed an intelligent clinician AI assistant using Oracle Cloud Infrastructure and Oracle AI Database to streamline communication and improve access to critical information.
This AI-driven solution is designed to support, not replace, medical professionals by reducing administrative burden and enabling faster access to accurate scientific insights. Built with strong safeguards, curated knowledge, and compliance considerations, the platform ensures trusted and responsible AI use in healthcare environments. Looking ahead, Mirxes plans to expand this capability into a broader data and AI platform that integrates clinical and genomic data, enabling more advanced diagnostics and improved patient care.
Follow us here:
LinkedIn: https://social.ora.cl/60035eXuF
X: https://social.ora.cl/6008abVgG
Instagram: https://social.ora.cl/60095eXDN
Facebook: https://social.ora.cl/60065enQp
